Anin G S Queency Stylin, B Shanthi, Anin G S Jenolin, L M Sweety
{"title":"Diagnostic insights into Trisomy 21: a case of abnormal Inhibin A, beta-hCG, AFP, and ultrasound findings.","authors":"Anin G S Queency Stylin, B Shanthi, Anin G S Jenolin, L M Sweety","doi":"10.1080/13813455.2026.2734608","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Trisomy 21, caused by the presence of an extra chromosome 21, results in Down syndrome (DS). Maternal biochemical markers and prenatal sonographic findings are valuable for assessing the risk of Trisomy 21, although they are not definitive for diagnosis. <b>Case Presentation</b>: The biochemical markers evaluated included Inhibin A, β-hCG, and alpha-fetoprotein (AFP). Elevated Inhibin A and β-hCG levels and reduced AFP levels are associated with an increased risk of Trisomy 21. Sonographic findings, including an echogenic cardiac focus and mild renal pelvicalyceal prominence, may represent normal variants but can be associated with a slightly increased risk of chromosomal abnormalities. In the present case, the combination of these sonographic findings and abnormal serum marker levels raised suspicion of Trisomy 21 or other fetal conditions. Genetic counselling was advised, with further diagnostic evaluation by amniocentesis or chorionic villus sampling (CVS). <b>Conclusion</b>: The combined interpretation of maternal serum biochemical markers and prenatal sonographic findings may assist in identifying pregnancies at increased risk of Trisomy 21 and guide the need for further diagnostic evaluation.</p>","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"1-4"},"PeriodicalIF":3.2000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2026.2734608","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Trisomy 21, caused by the presence of an extra chromosome 21, results in Down syndrome (DS). Maternal biochemical markers and prenatal sonographic findings are valuable for assessing the risk of Trisomy 21, although they are not definitive for diagnosis. Case Presentation: The biochemical markers evaluated included Inhibin A, β-hCG, and alpha-fetoprotein (AFP). Elevated Inhibin A and β-hCG levels and reduced AFP levels are associated with an increased risk of Trisomy 21. Sonographic findings, including an echogenic cardiac focus and mild renal pelvicalyceal prominence, may represent normal variants but can be associated with a slightly increased risk of chromosomal abnormalities. In the present case, the combination of these sonographic findings and abnormal serum marker levels raised suspicion of Trisomy 21 or other fetal conditions. Genetic counselling was advised, with further diagnostic evaluation by amniocentesis or chorionic villus sampling (CVS). Conclusion: The combined interpretation of maternal serum biochemical markers and prenatal sonographic findings may assist in identifying pregnancies at increased risk of Trisomy 21 and guide the need for further diagnostic evaluation.
期刊介绍:
Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders.
The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications.
Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics:
-Dysregulation of hormone receptors and signal transduction
-Contribution of gene variants and gene regulatory processes
-Impairment of intermediary metabolism at the cellular level
-Secretion and metabolism of peptides and other factors that mediate cellular crosstalk
-Therapeutic strategies for managing metabolic diseases
Special issues dedicated to topics in the field will be published regularly.